CN102260244A - Stable rabeprazole sodium compound - Google Patents
Stable rabeprazole sodium compound Download PDFInfo
- Publication number
- CN102260244A CN102260244A CN2011102280910A CN201110228091A CN102260244A CN 102260244 A CN102260244 A CN 102260244A CN 2011102280910 A CN2011102280910 A CN 2011102280910A CN 201110228091 A CN201110228091 A CN 201110228091A CN 102260244 A CN102260244 A CN 102260244A
- Authority
- CN
- China
- Prior art keywords
- sodium rabeprazole
- compound
- rabeprazole
- sodium
- adds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention belongs to the technical field of medicines and particularly relates to a rabeprazole sodium compound and a preparation method thereof. Rabeprazole sodium provided by the invention contains less water and has the advantages of chemical purity up to 99.9%, maximum impurity content less than 0.1%, optical purity up to 99.96%ee and good stability. The compound provided by the invention has low production cost and stable quality, and is suitable for industrial production.
Description
Technical field
The invention belongs to medical technical field, be specifically related to sodium rabeprazole compound and preparation method thereof.
Background technology
Hydrochloric acid in gastric juice can help digest, if but hyperchlorhydria can injure stomach, duodenum on the contrary.Work as gastroxia, the symptom of acid regurgitation, acid regurgitation, sour regurgitation can occur, except meeting causes stomach, duodenal ulcer, also can cause reflux esophagitis.The disease that stomach, duodenal ulcer right and wrong are usually seen as untimely treatment, also can cause many severe complications, as hemorrhage, pyloric obstruction, perforation, in addition canceration, threat to life.And reflux esophagitis also increases year by year at China's sickness rate.So the too much secretion of gastric acid inhibitory seems particularly important.Clinically, Chang Yong acid inhibitor has three kinds: antacid, proton pump inhibitor (PPIs) and H
2Receptor antagonist.
The appearance of proton pump inhibitor has promoted the development of gastroenterology, and a series of analysis-by-synthesis shows, no matter is to press down sour onset speed or pressing down on the effect of acid antacid that proton pump inhibitor all is better than and H
2Receptor antagonist, it is more obvious especially the curative effect of disease to be increased in reflux esophagitis, peptide ulceration and Te Fa gastric acid secretion
[3]So proton pump inhibitor is a gastric acid inhibitory excretory choice drug clinically.First-generation proton pump inhibitor omeprazole, pantoprazole and lansoprazole, because there are certain limitation in its pharmacodynamics and pharmacokinetics aspect, influenced its curative effect, slow as onset time, need repeatedly take medicine just can reach maximum and press down sour effect, can not press down acid in 24 hours, has the night acid rebound to take place, promote that effect instability, the interactional incidence of clinical medicine metabolic of ulcer healing and remission are more high.And by comparison, there is remarkable advantages in rabeprazole pharmacodynamics pharmacokinetics, its bioavailability height, rapid-action, can be comprehensive and the secretion of long-acting gastric acid inhibitory.In addition, rabeprazole can be non-competing ground, irreversibly suppress the urase of helicobacter pylori, reach the effect of anti-helicobacter pylori, and helicobacter pylori is one of principal element that causes stomach, duodenal ulcer
[3]
A large amount of clinical datas show that Sodium rabeprazole short-term and long-term prescription security are good.FDA relevant expert once estimated some documents, inferred that patient's life-time service PPIs of helicobacter pylori infection can not promote atrophic gastritis, intestinesization are living or the generation of cancer of the stomach
[4]And, to compare with in the past PPIs, life-time service Sodium rabeprazole treatment gastrinoma can not only more effective control hydrochloric acid in gastric juice level, can also prevent that its histology from further changing.The Sodium rabeprazole side effect is little, better tolerance, and relative side effect is headache, fash, diarrhoea and cold symptoms etc., but can tolerate.In the time of going on the market surplus in the of ten year, the researchist constantly studies it, has fully verified its validity and security.It presses down sour effect and the anti-helicobacter pylori effect has surpassed all proton pump inhibitors in the past, and similar to latest generation proton pump inhibitor esomeprazole, but its price is lower than esomeprazole, is more suitable for the general patient medication.So we have reason to believe that Sodium rabeprazole will become the first-selected curative in the acid inhibitor, benefit extensive patients.
As everyone knows, because the disease clinical onset rate that gastroxia causes is very high, sickness rate just surpasses more than 10% among stomach, the duodenal ulcer crowd, people in the U.S. more than 44% has heartburn symptom (for the reflux esophagitis cardinal symptom), and reflux esophagitis is at China's sickness rate also cumulative year after year, so very big for the demand of acid inhibitor.
Press down sour medicine as the most promising, the Sodium rabeprazole that existing market is sold exists enteric coated tablet and two kinds of formulations of enteric coated capsule simultaneously.Relative tablet, capsule has many advantages: (1) capsule shell can be covered the unpleasant odor of medicine; (2) capsule shell can completely cut off contacting of medicine and light, air and moisture, improves medicine stability; (3) preparation because of capsule does not generally add vehicle, and also plus-pressure not so disperse fast, good absorption than pill, tablet in stomach and intestine, can improve bioavailability of medicament.
In the face of the more than one hundred million patient of China, the Sodium rabeprazole medicine of selling on the existing market can not satisfy the market requirement that enlarges day by day.My researchist of company is through repeatedly experiment, filter out optimum pharmaceutical adjunct, on the basis that cost reduces, also guaranteed quality, not only have the curative effect suitable with import drugs, the while reasonable price, especially need to be fit to the patient of long-term prescription, when meeting the need of market, also to have benefited extensive patients.
Sodium rabeprazole was developed by Japanese Eisai Co., Ltd, goes on the market in the Britain and the U.S. respectively in 1998,1999 afterwards in Japanese Initial Public Offering in 1997, and China food and medicine Surveillance Authority ratified its import, trade(brand)name: Pariet in 2000.Sodium rabeprazole is proton pump inhibitor (PPIs), the effectively secretion of gastric acid inhibitory.Clinical treatment stomach, duodenal ulcer, reflux esophagitis and the Zhuo-Emhorn syndrome of being mainly used in, common dose is 10mg and 20mg.
Sodium rabeprazole
Chemical name: the 2-[[[4-(3-methoxy propoxy)-3-methyl-2-pyridyl] methyl] sulfinyl]-1H-benzoglyoxaline sodium;
Molecular formula: C
18H
20N
3O
3SNa;
Molecular weight: 381.43;
Proterties: this product is white or off-white color particle and powder;
Structural formula:
The Sodium rabeprazole structural formula
The pharmacology type: Sodium rabeprazole is the potent inhibitor of benzimidazoles parietal cell most advanced and sophisticated secretion film endoplasm pump (being proton pump).
Mechanism of action: Sodium rabeprazole can suppress the H+-K+-ATP enzymic activity of parietal cell, thus the secretion of gastric acid inhibitory.
Indication: stomach ulcer, duodenal ulcer, stoma ulcer, reflux esophagitis, Zhuo-Emhorn (Zollinger-Ellison) syndrome.
Usage and dosage: usually, oral 1 Sodium rabeprazole meter 10mg every day that is grown up, but according to oral 1 20mg of the state of an illness also every day.In the ordinary course of things, be that be 6 weeks the course of treatment of 8 weeks, duodenal ulcer the course of treatment of stomach ulcer, stoma ulcer, reflux esophagitis.
Rabeprazole comprises left-handed and two kinds of optical isomers of dextrorotation, actual employed activeconstituents is the racemic mixture of two kinds of optical isomers, but experiment shows that the pharmacological action of rabeprazole dextrorotatory isomer will obviously be better than the levoisomer and the little selected topic thereof, its dextrorotatory isomer subliminal dose is little than raceme, metabolic half life is long, can obviously improve the generation of curative effect and reduction toxic side effects.
Patent documentation about the Sodium rabeprazole preparation is many, as US5045552, US20050234103, WO2006117802, US20080161579, WO2006024890, WO03101452 or the like, all used sodium hydroxide and rabeprazole in alcohol or water, to react in these patents, generate Sodium rabeprazole, but all have certain problem.
1) with aqueous sodium hydroxide solution and rabeprazole reaction, adopt freeze drying process to obtain Sodium rabeprazole then, as patent WO03101452, this method exists facility investment big, energy consumption height, weakness such as production cycle length.
2) with aqueous sodium hydroxide solution or alcoholic solution and rabeprazole reaction, concentrate repeatedly then, residue is used other solvent crystallizations again, gets Sodium rabeprazole, as patent US5045552, US20050234103, US20080161579, WO2006024890.This method needs to concentrate repeatedly, makes product decomposition, variable color easily; The concentrating residues thing is a syrupy shape in addition, sticks to reactor vessel wall easily and stirs, and when using other solvent crystallizations again, may occur that crystallization is incomplete, yield is low, the energy consumption height.
3) with aqueous sodium hydroxide solution and rabeprazole reaction, use dichloromethane extraction then, concentrate methylene dichloride, use the acetic acid ethyl dissolution enriched material, with inert solvent Sodium rabeprazole is separated out again, as patent WO2006117802.Because the solubleness of Sodium rabeprazole in water is bigger, when extraction, need to make system saturated with a large amount of sodium-chlor earlier, use a large amount of dichloromethane extraction again, so it is difficult to contain a large amount of sodium-chlor in the waste water, and same the existence needs spissated problem.
In research process, repeat the method for above-mentioned patent documentation, the rabeprazole sodium impurity number that obtains is more, and total impurities is higher, and optical purity is low.The Sodium rabeprazole that the present invention obtains, the advantage that has: chemical purity height, maximum contaminant be less than 1 ‰, the optical purity height; Good stability is especially to wet good stability.
Summary of the invention
One object of the present invention discloses a kind of sodium rabeprazole compound.
Another object of the present invention discloses the preparation method of sodium rabeprazole compound.
Another purpose of the present invention discloses the pharmaceutical composition that comprises sodium rabeprazole compound.
Now content of the present invention is specifically described in conjunction with purpose of the present invention.
The invention provides a kind of sodium rabeprazole compound (shown in the formula I),
（Ⅰ）
Karl Fischer method (Karl Fischer method) is in a kind of all kinds of chemical processes of measuring moisture in the material, and, the most accurately method the most single-minded to water has been listed in the standard method of moisture determination in many materials, organic compound especially, reliable results.Through 6 batches of mensuration, its moisture is less than 1 ‰:
| Batch | Moisture (‰) | Batch | Moisture (‰) |
| 1 | 0.15 | 4 | 0.19 |
| 2 | 0.21 | 5 | 0.20 |
| 3 | 0.18 | 6 | 0.13 |
This sodium rabeprazole compound crystal adopts D/Max-2500.9161 type x-ray diffractometer to measure condition determination: Cu Ka target, tube voltage 40KV, tube current 100mA.X-ray powder diffraction charateristic avsorption band (2 θ) and D value are as follows,
| Peak number | 2 θ angles (°) measured value | D() measured value | I/I 0 |
| 1 | 4.920 | 17.9461 | 100 |
| 2 | 9.900 | 8.9270 | 38 |
| 3 | 11.700 | 7.5574 | 2 |
| 4 | 12.420 | 7.1208 | 1 |
| 5 | 14.920 | 5.9328 | 27 |
| 6 | 16.160 | 5.4803 | 2 |
| 7 | 18.280 | 4.8492 | 2 |
| 8 | 19.500 | 4.5485 | 80 |
| 9 | 20.880 | 4.2509 | 4 |
| 10 | 22.640 | 3.9242 | 2 |
| 11 | 23.360 | 3.8049 | 6 |
| 12 | 24.340 | 3.6539 | 4 |
| 13 | 24.740 | 3.5957 | 4 |
| 14 | 25.120 | 3.5421 | 3 |
| 15 | 26.240 | 3.3934 | 4 |
| 16 | 26.580 | 3.3508 | 4 |
| 17 | 27.980 | 3.1862 | 3 |
| 18 | 29.000 | 3.0764 | 3 |
| 19 | 30.220 | 2.9550 | 7 |
| 20 | 30.440 | 2.9341 | 5 |
See Fig. 1.
The mensuration of 2 θ values is used light source among the present invention, and precision is ± 0.2 °, therefore represents above-mentioned value of getting to allow certain reasonably limit of error, and its limit of error is ± 0.2 °.
The fusing point of this crystal formation is 242 ℃-242.5 ℃, presses the method for Chinese Pharmacopoeia and measures, and this is that those skilled in the art are in common knowledge.
Another object of the present invention discloses sodium rabeprazole compound crystalline preparation method,
Specifically comprise the following steps:
1) Sodium rabeprazole adds in 5-10 times of (weight or measurement (WM) ratio) water, adds the dimethyl formamide (DMF) of Sodium rabeprazole 0.5%-1% in the above-mentioned aqueous solution, stirs 30 minutes, filters, and filtrate is cooled to 5 ℃-10 ℃, and is standby;
2) mixed solution with Sodium rabeprazole 18-20 times acetonitrile-methyl ethyl ketone=5:3 is cooled to 5 ℃-10 ℃, adds above-mentioned stock solution, is incubated 15-20 hour, separates out crystallization, filters, and drying obtains.Chemical purity is up to 99.9%, and maximum contaminant is less than 1 ‰, and optical purity is up to more than the 99.9%ee.
Among the above-mentioned preparation method, Sodium rabeprazole moisture is low, and good stability can guarantee the quality of pharmaceutical preparation.
The chemical structure of used Sodium rabeprazole proves that through determination of elemental analysis chemical structure is correct.
Another purpose of the present invention provides the composition that comprises the sodium rabeprazole compound that the pharmaceutically acceptable carrier of sodium rabeprazole compound crystal and one or more forms.
Preparation of pharmaceutical compositions of the present invention is as follows: use standard and conventional technology; acceptable solid or liquid vehicle are combined, and make it at random to combine and be prepared into particulate or microballoon with acceptable auxiliary and vehicle on the technology of pharmaceutics.Said composition is used to prepare oral preparations, injection.
The amount of the active ingredient that contains in pharmaceutical composition and the unit dosage form (The compounds of this invention) can be according to patient's the state of an illness, specific being applied of situation of diagnosis, the amount of used compound or concentration are regulated in the scope of a broad, and the weight range of active compound is 1%～30%(weight of composition).
Stability test
The contriver studies the stability of crystal formation of the present invention, and the investigation condition is a high temperature (60 ℃ ± 2 ℃), (4500Lx ± 500lx), (92.5%, RH) investigate index is outward appearance, content and related substance to high humidity to strong illumination.
The result: under high light, high temperature, super-humid conditions from 0-15 days, outward appearance, related substance, content do not change, and illustrates that chemical stability is good, the manufacturing and the standing storage of suitable pharmaceutical preparation.
At 40 ℃, under different relative humidity (RH) conditions (75%, 92.5%), the mensuration of moisture in the sodium rabeprazole compound crystal:
The result: at 40 ℃, under different relative humidity (RH) conditions (75%, 92.5%), it is constant that moisture keeps, and explanation has good stability, and is fit to the manufacturing and the standing storage of pharmaceutical preparation.
Figure of description:
Fig. 1, sodium rabeprazole compound X-ray diffraction in crystals figure;
Embodiment:
The present invention is described further below in conjunction with embodiment, makes this area professional and technical personnel better understand the present invention.Embodiment only is indicative, means that never it limits the scope of the invention by any way.
Used Sodium rabeprazole purity 98.3% (HPLC normalization method) among the present invention, optical purity 99.1%ee, its chemical structure proves that through determination of elemental analysis chemical structure is correct.
Results of elemental analyses:
Measured value (calculated value), C:56.68 (56.68), H:5.29 (5.30), N:11.02 (11.00),
O:12.58(12.59)?,?S:8.41(8.40)；
The proof chemical structure is correct.
Embodiment 1
In the 500ml reaction flask of stirring, thermometer, condenser is housed, add 60 gram Sodium rabeprazole and 300 ml waters, in the above-mentioned aqueous solution, add 0.5 gram dimethyl formamide (DMF), stirred 30 minutes, to filter, filtrate is cooled to 12 ℃, and is standby.
The mixed solution of 1150ml acetonitrile-methyl ethyl ketone=5:5 is cooled to 13 ℃, stirs the above-mentioned stock solution of adding down, be incubated 18 hours, separate out crystallization, filter, drying obtains white crystals 53.3 grams.Measure 3 times through the karl Fischer method, get average, contain the moisture of 2.40% (weight percent).Purity 99.9% (HPLC normalization method), optical purity 99.96%ee (chirality HPLC).
Results of elemental analyses:
Measured value (calculated value), C:56.68 (56.68), H:5.29 (5.29), N:11.02 (11.01),
O:12.58(12.60)?,?S:8.41(8.40)。
This crystalline X-ray diffractogram is seen Fig. 1.Instrument model and condition determination: Japanese D/max 2500 type diffractometers of science; CuKa 40Kv 100mA; 2 θ sweep limit: 0-50
°
Embodiment 2
Contain the sodium rabeprazole compound capsule
Prescription: sodium rabeprazole compound 20 grams, N.F,USP MANNITOL 100 grams, lactose 140 grams, lime carbonate 50 grams, Magnesium Stearate 5 grams, 8% ethyl cellulose solution is an amount of, and 1000 of enteric coated capsulees are made 1000.
Technology: get sodium rabeprazole compound, N.F,USP MANNITOL, lactose, lime carbonate and mix; Add suitable amount of adhesive 8% ethyl cellulose solution system softwood, 20 eye mesh screens are granulated, 40 ℃ ± 2 ℃ oven dry, and whole grain is mixed Magnesium Stearate outside adding and is mixed, the dress capsule, promptly.
Claims (4)
1. sodium rabeprazole compound shown in the formula I,
（Ⅰ）
The crystal of described sodium rabeprazole compound, as in the characteristic X-ray powder mensuration, its collection of illustrative plates has following 2 θ diffraction angle and D value with the CuKa ray,
The error of 2 θ diffraction angle is ± 0.2.
2. the described sodium rabeprazole compound crystalline of claim 1 preparation method comprises the steps:
1) Sodium rabeprazole adds in 5-10 times of (weight or measurement (WM) ratio) water, adds the dimethyl formamide (DMF) of Sodium rabeprazole 0.5%-1% in the above-mentioned aqueous solution, stirs 30 minutes, filters, and filtrate is cooled to 5 ℃-10 ℃, and is standby;
2) mixed solution with Sodium rabeprazole 18-20 times acetonitrile-methyl ethyl ketone=5:3 is cooled to 5 ℃-10 ℃, adds above-mentioned stock solution, is incubated 15-20 hour, separates out crystallization, filters, and drying obtains.Chemical purity is up to 99.9%, and maximum contaminant is less than 1 ‰, and optical purity is up to more than the 99.9%ee.
3. the composition of the sodium rabeprazole compound of forming according to the pharmaceutically acceptable carrier of the described sodium rabeprazole compound crystal of claim 1 and one or more.
4. composition according to claim 3 is characterized in that said composition is used to prepare solid preparation, injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110228091 CN102260244B (en) | 2011-08-10 | 2011-08-10 | Stable rabeprazole sodium compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110228091 CN102260244B (en) | 2011-08-10 | 2011-08-10 | Stable rabeprazole sodium compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102260244A true CN102260244A (en) | 2011-11-30 |
| CN102260244B CN102260244B (en) | 2013-04-10 |
Family
ID=45007110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110228091 Active CN102260244B (en) | 2011-08-10 | 2011-08-10 | Stable rabeprazole sodium compound |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102260244B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103709141A (en) * | 2013-10-14 | 2014-04-09 | 寿光富康制药有限公司 | Crystal forms and amorphous forms of rabeprazole sodium |
| CN104072482A (en) * | 2014-06-17 | 2014-10-01 | 江苏奥赛康药业股份有限公司 | Rabeprazole sodium compound and pharmaceutical composition thereof |
| CN109111428A (en) * | 2017-06-23 | 2019-01-01 | 南京海润医药有限公司 | A kind of dextral-rabeprazole sodium compound and its pharmaceutical composition |
| CN109111429A (en) * | 2017-06-23 | 2019-01-01 | 南京海润医药有限公司 | Dextral-rabeprazole sodium compound and its pharmaceutical composition |
| CN113336741A (en) * | 2021-05-07 | 2021-09-03 | 湖南德虹制药有限公司 | Rabeprazole sodium anhydrate crystal form and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101627996A (en) * | 2009-08-20 | 2010-01-20 | 山东罗欣药业股份有限公司 | Rabeprazole sodium composition and preparation method thereof |
| CN101704811A (en) * | 2009-12-09 | 2010-05-12 | 陶灵刚 | High-purity sodium rabeprazole compound |
-
2011
- 2011-08-10 CN CN 201110228091 patent/CN102260244B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101627996A (en) * | 2009-08-20 | 2010-01-20 | 山东罗欣药业股份有限公司 | Rabeprazole sodium composition and preparation method thereof |
| CN101704811A (en) * | 2009-12-09 | 2010-05-12 | 陶灵刚 | High-purity sodium rabeprazole compound |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103709141A (en) * | 2013-10-14 | 2014-04-09 | 寿光富康制药有限公司 | Crystal forms and amorphous forms of rabeprazole sodium |
| CN104072482A (en) * | 2014-06-17 | 2014-10-01 | 江苏奥赛康药业股份有限公司 | Rabeprazole sodium compound and pharmaceutical composition thereof |
| CN109111428A (en) * | 2017-06-23 | 2019-01-01 | 南京海润医药有限公司 | A kind of dextral-rabeprazole sodium compound and its pharmaceutical composition |
| CN109111429A (en) * | 2017-06-23 | 2019-01-01 | 南京海润医药有限公司 | Dextral-rabeprazole sodium compound and its pharmaceutical composition |
| CN113336741A (en) * | 2021-05-07 | 2021-09-03 | 湖南德虹制药有限公司 | Rabeprazole sodium anhydrate crystal form and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102260244B (en) | 2013-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2207339C2 (en) | Omeprazole form a, method for its preparing, pharmaceutical preparation based on thereof and method of treatment of gastroenteric disturbances | |
| CN102351857B (en) | Tropiseiron hydrochloride compound | |
| JP5799011B2 (en) | Mangiferin berberine salt and its preparation and use | |
| CN102260244B (en) | Stable rabeprazole sodium compound | |
| CN101687848A (en) | Solid state forms of racemic ilaprazole | |
| CN102367252A (en) | Tropisetron hydrochloride compound | |
| WO2024060911A1 (en) | Benzoisothiazole compound, and pharmaceutical composition and use thereof | |
| CN102321072B (en) | Esomeprazole sodium hemihydrate | |
| CN102234265B (en) | Lansoprazole compound | |
| CN103772360A (en) | New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt | |
| CN104447611A (en) | Acotiamide compound | |
| WO2014056396A1 (en) | Flumatinib mesylate crystal form and preparation method and use thereof | |
| WO2024082917A1 (en) | Crystal form a of bupivacaine-meloxicam salt, single crystal thereof, preparation method therefor and use thereof | |
| NZ538966A (en) | Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate | |
| WO2016078594A1 (en) | Pyrrole ring-containing proton pump inhibitor being hemifumarate and crystal form thereof, intermediate and medical use thereof | |
| TWI664172B (en) | Crystal form of lenalidomide, preparation method and application thereof | |
| CN114989138B (en) | Vonoprazan salt and crystal form, preparation method and application thereof | |
| JP2013509357A (en) | 3- (Substituted dihydroisoindol-2-yl) -2,6-piperidinedione polycrystal and medicinal composition | |
| CN104447612A (en) | Acotiamide hydrate crystal form and its preparation method and use | |
| CN104072482A (en) | Rabeprazole sodium compound and pharmaceutical composition thereof | |
| JP6130595B2 (en) | Crystalline pyrroloquinoline quinone lithium salt, preparation method and application | |
| CN103772355B (en) | Sodium rabeprazole compound | |
| CN102659644B (en) | Crystal forms of 2-aminoethyl sulfonic acid and preparation processes for crystal forms | |
| CN105399725B (en) | Bent its salt of Ge Lieting compounds, crystal, pharmaceutical composition and purposes | |
| CN104447722A (en) | Canagliflozin compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180921 Address after: 300409 88 Huashi Road, Beichen science and Technology Park, Tianjin Patentee after: TIANJIN HANRUI PHARMACEUTICAL CO., LTD. Address before: 300203 Tianjin Hexi District Dagu South Road 4, 3 Patentee before: Tianjin Hankang Pharmaceutical Biotechnology Co., Ltd. |